A multicenter Italian study of amineptine (Survector 100)

Area of Science:

• Pharmacology
• Clinical Psychiatry
• Neuroscience

Background:

• Depressive disorders represent a significant global health burden.
• Identifying effective and safe antidepressant treatments remains a priority in psychiatric research.

Purpose of the Study:

• To evaluate the antidepressant efficacy and safety of amineptine.
• To assess the onset and spectrum of amineptine's therapeutic action in a large patient cohort.

Main Methods:

• A national multicenter open clinical trial involving 32 hospitals.
• 324 patients diagnosed with depressive disorders (DSM-III/INSERM) received amineptine (200 mg/day) for a mean of 40 days.
• Efficacy assessed via Hamilton Depression Rating Scale (HDRS) and diagnostic subgroup analysis.

Main Results:

• Amineptine showed significant antidepressant efficacy with a rapid onset of action starting on day 7.
• High improvement rates observed: 90% in reactive/neurotic depression and dysthymic disorders.
• Effective in 76% of patients with psychotic depression and major depressive episodes.
• Amineptine exhibited a low frequency of side effects and good clinical, biological, and cardiovascular acceptability.

Conclusions:

• Amineptine is a safe and effective antidepressant with a broad spectrum of activity.
• The drug offers a rapid onset of action, making it a valuable option for treating diverse depressive disorders.
• The favorable safety profile and tolerability support amineptine's clinical utility.